LEADER 02135nam  2200553   450 
001 9910456268603321
005 20200520144314.0
010   $a1-4698-7726-0
035   $a(CKB)2430000000022234
035   $a(EBL)3418597
035   $a(SSID)ssj0000352645
035   $a(PQKBManifestationID)11275815
035   $a(PQKBTitleCode)TC0000352645
035   $a(PQKBWorkID)10285557
035   $a(PQKB)10719481
035   $a(MiAaPQ)EBC2032676
035   $a(Au-PeEL)EBL2032676
035   $a(CaPaEBR)ebr10834566
035   $a(OCoLC)908076220
035   $a(EXLCZ)992430000000022234
100   $a20020722h20022002  uy|            0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAntiepileptic drugs /$feditors, Rene? H. Levy [and three others]
205   $aFifth edition.
210  1$aPhiladelphia :$cLippincott Williams & Wilkins,$d[2002]
210  4$dİ2002
215   $a1 online resource (987 p.)
300   $aDescription based upon print version of record.
311   $a0-7817-2321-3 
320   $aIncludes bibliographical references and index.
327   $asection I. General principles -- section II. Benzodiazepines -- section III. Carbamazepine -- section IV. Felbamate -- section V. Gabapentin -- section VI. Lamotrigine -- section VII. Levetiracetam -- section VIII. Oxcarbazepine -- section IX. Phenobarbital and other barbiturates -- section X. Phenytoin and other hydantoins -- section XI. Primidone -- section XII. Succinimides -- section XIII. Tiagabine -- section XIV. Topiramate -- section XV. Valproic acid -- section XVI. Vigabatrin -- section XVII. Zonisamide -- section XVIII. Drugs in development.
606   $aEpilepsy$xChemotherapy
606   $aAnticonvulsants
608   $aElectronic books.
615  0$aEpilepsy$xChemotherapy.
615  0$aAnticonvulsants.
676   $a616.8/53061
701   $aLevy$b Rene? H$0979868
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910456268603321
996   $aAntiepileptic drugs$92234820
997   $aUNINA